Graft-Versus-Host Disease and Graft-Versus-Tumor Immunity

Core Idea

In hematopoietic stem cell transplantation, donor immune cells can attack recipient tissues (graft-versus-host disease, GVHD), causing severe morbidity and mortality. Paradoxically, donor T cells also attack remaining leukemic cells (graft-versus-tumor, GVT effect). This creates a therapeutic window: selective enhancement of GVT while minimizing GVHD is a major challenge in transplantation.

How It's Best Learned

Study acute GVHD (target: skin, GI tract, liver) versus chronic GVHD (fibrotic, autoimmune-like). Examine how T cell depletion reduces GVHD but increases relapse.

Common Misconceptions

GVHD is not simply 'rejection in reverse'; it involves donor T cells attacking recipient tissues. Not all recipients receiving allogeneic transplants develop GVHD; T cell depletion or immunosuppression can prevent it.

Explainer

From your study of transplant immunology and graft rejection, you understand that the recipient's immune system normally attacks foreign tissue because it recognizes donor MHC molecules as non-self. Graft-versus-host disease (GVHD) flips this relationship: it occurs when the *graft* attacks the *host*. This is possible because hematopoietic stem cell transplants (bone marrow transplants) contain mature donor T cells alongside the stem cells. If the recipient's tissues express MHC molecules that differ from the donor's — as they will in any allogeneic (non-identical) transplant — donor T cells will recognize recipient cells as foreign and mount an immune attack against the patient's own body.

Acute GVHD typically develops within the first 100 days after transplant and targets three organs with high epithelial turnover: the skin (rash, sometimes progressing to blistering), the gastrointestinal tract (severe diarrhea, abdominal pain, mucosal sloughing), and the liver (jaundice from bile duct damage). The pathophysiology begins with tissue damage from the pre-transplant conditioning regimen (chemotherapy and radiation), which releases inflammatory cytokines like TNF-α and IL-1 that activate donor T cells. These T cells — both CD4+ and CD8+ — then recognize host alloantigens on recipient antigen-presenting cells, proliferate, and infiltrate target organs. Chronic GVHD develops later and resembles autoimmune diseases: fibrosis of the skin, dry eyes and mouth, bronchiolitis obliterans in the lungs, and widespread connective tissue damage driven by dysregulated immunity and loss of tolerance mechanisms.

Here is the paradox that makes GVHD clinically fascinating: the same donor T cells that cause GVHD also attack residual leukemia cells in the recipient. This graft-versus-tumor (GVT) or graft-versus-leukemia effect is one of the most powerful anti-cancer mechanisms in medicine. Patients who develop mild GVHD after transplant for leukemia have significantly lower relapse rates than those who do not. The evidence is stark — when T cells are depleted from the graft to prevent GVHD, leukemia relapse rates climb dramatically.

This creates a therapeutic dilemma: too much immunosuppression prevents GVHD but allows cancer relapse; too little allows GVHD to cause life-threatening organ damage. Modern strategies try to thread this needle. Donor lymphocyte infusions give additional donor T cells after transplant to boost GVT in patients showing signs of relapse. Selective T cell depletion aims to remove alloreactive T cells (those causing GVHD) while preserving anti-tumor T cells. Regulatory T cell infusions attempt to suppress GVHD without ablating GVT. The ultimate goal — complete separation of GVHD from GVT — remains one of the central unsolved problems in transplantation medicine.